Molecular and immune targets for Merkel cell carcinoma therapy and prevention
Open Access
- 22 May 2019
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (9) , 1602-1611
Abstract
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, for which the exact mechanisms of carcinogenesis remain unknown. Therapeutic options for this highly aggressive malignancy have historically been limited in both their initial response and response durability. Recent improvements in our understanding of MCC tumor biology have expanded therapeutic options for these patients, namely through the use of immunotherapies such as immune checkpoint inhibitors. Further elucidation of the tumor mutational landscape has identified molecular targets for therapies, which have demonstrated success in other cancer types. In this review, we discuss both current and investigational immune and molecular targets of therapy for MCC.Keywords
Funding Information
- Campbell Family Foundation
This publication has 98 references indexed in Scilit:
- Multicolor microRNA FISH effectively differentiates tumor typesJournal of Clinical Investigation, 2013
- Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirusJournal of Clinical Investigation, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based StudyClinical Cancer Research, 2012
- Activation of the PI3K/AKT Pathway in Merkel Cell CarcinomaPLOS ONE, 2012
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death & Differentiation, 2011
- Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of SurvivalJournal of Clinical Oncology, 2011
- A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin)American Journal of Clinical Oncology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- The PARP superfamilyBioEssays, 2004